Two CAR-T19 cell products were approved for the treatment of B-ALL and diffuse large B cell lymphoma (DLBCL) by the FDA: tisagenlecleucel with 4-1BB ICOS and axicabtagene ciloleucel with CD28 ICOS. The gene discussed is CD28; the disease is diffuse large B-cell lymphoma.